MA25087A1 - Procedes et produits intermediaires pour la preparation de composes anti-cancereux - Google Patents

Procedes et produits intermediaires pour la preparation de composes anti-cancereux

Info

Publication number
MA25087A1
MA25087A1 MA25940A MA25940A MA25087A1 MA 25087 A1 MA25087 A1 MA 25087A1 MA 25940 A MA25940 A MA 25940A MA 25940 A MA25940 A MA 25940A MA 25087 A1 MA25087 A1 MA 25087A1
Authority
MA
Morocco
Prior art keywords
products
preparation
cancer compounds
intermediate processes
processes
Prior art date
Application number
MA25940A
Other languages
English (en)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA25087A1 publication Critical patent/MA25087A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25940A 1999-03-31 2000-03-29 Procedes et produits intermediaires pour la preparation de composes anti-cancereux MA25087A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
MA25087A1 true MA25087A1 (fr) 2000-10-01

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25940A MA25087A1 (fr) 1999-03-31 2000-03-29 Procedes et produits intermediaires pour la preparation de composes anti-cancereux

Country Status (50)

Country Link
US (1) US6476040B1 (fr)
EP (1) EP1044969B1 (fr)
JP (2) JP3420549B2 (fr)
KR (2) KR100430210B1 (fr)
CN (2) CN100351242C (fr)
AP (2) AP1655A (fr)
AR (1) AR018705A1 (fr)
AT (1) ATE348098T1 (fr)
AU (2) AU781402B2 (fr)
BG (1) BG65194B1 (fr)
BR (1) BRPI0001486B8 (fr)
CA (2) CA2427221C (fr)
CO (1) CO5160273A1 (fr)
CR (1) CR6165A (fr)
CZ (1) CZ299426B6 (fr)
DE (1) DE60032275T2 (fr)
DK (1) DK1044969T3 (fr)
DZ (1) DZ3030A1 (fr)
EA (3) EA005892B1 (fr)
EE (1) EE04589B1 (fr)
EG (1) EG22506A (fr)
ES (1) ES2278578T3 (fr)
GE (1) GEP20022653B (fr)
GT (1) GT200000037A (fr)
HK (1) HK1029790A1 (fr)
HR (1) HRP20000182B1 (fr)
HU (1) HU227698B1 (fr)
ID (1) ID25427A (fr)
IL (2) IL168036A (fr)
IS (1) IS2468B (fr)
MA (1) MA25087A1 (fr)
MY (1) MY136270A (fr)
NO (2) NO321952B1 (fr)
NZ (2) NZ512818A (fr)
OA (1) OA11335A (fr)
PA (1) PA8491901A1 (fr)
PE (1) PE20001599A1 (fr)
PL (1) PL339330A1 (fr)
PT (1) PT1044969E (fr)
RS (1) RS49836B (fr)
SG (2) SG115536A1 (fr)
SK (1) SK287339B6 (fr)
SV (1) SV2002000047A (fr)
TN (1) TNSN00064A1 (fr)
TR (1) TR200000837A2 (fr)
TW (1) TW553939B (fr)
UA (2) UA80955C2 (fr)
UY (1) UY26086A1 (fr)
YU (1) YU13200A (fr)
ZA (1) ZA200001586B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1408980A4 (fr) 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (fr) 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
ME01222B (me) 2005-02-28 2013-06-20 Eisai R&D Man Co Ltd Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (fr) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
CA2627598C (fr) * 2005-11-07 2013-06-25 Eisai R & D Management Co., Ltd. Utilisation d'une combinaison de substance anti-angiogenique et d'inhibiteur de kinase c-kit
WO2007061127A1 (fr) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Agent antitumeur pour myelomes multiples
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
WO2008012105A1 (fr) 2006-07-28 2008-01-31 Synthon B.V. Forme cristalline d'erlobtinib
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
EP2170844B1 (fr) * 2007-02-21 2016-05-04 Natco Pharma Limited Nouveaux polymorphes destinés de chlorhydrate d'erlotinibe et procédé de fabrication
EP2139868B1 (fr) 2007-04-04 2015-07-29 Cipla Limited Procédé de préparation de l'erlotinib et de ses sels pharmaceutiquement acceptables
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
EP2162444B1 (fr) 2007-07-11 2014-06-04 Hetero Drugs Limited Procédé amélioré de préparation de l'hydrochlorate d'erlotinibe
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
WO2009025875A1 (fr) * 2007-08-23 2009-02-26 Plus Chemicals Sa Formulations stables de chlorhydrate d'erlotinib cristallin
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
WO2009060945A1 (fr) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. Combinaison d'une substance antiangiogénique et d'un complexe de platine antitumoral
WO2009096377A1 (fr) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Utilisation combinée d'un inhibiteur de l'angiogenèse et d'un taxane
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (fr) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Procédés de préparation du chlorhydrate d'erlotinib
CA2995880C (fr) 2009-01-16 2021-01-05 Exelixis, Inc. Procedes de preparation de n-(4-{[6,7-bis(methyloxy)quinolein-4-yl]oxy}phenyl)(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (fr) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Procédé de synthèse de la forme a du chlorhydrate d'erlotinib et de la forme b du chlorhydrate d'erlotinib
WO2011068404A2 (fr) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
US8952022B2 (en) 2010-07-23 2015-02-10 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
WO2014118737A1 (fr) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2908441A1 (fr) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Procede de preparation d'erlotinib
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
CA2978226A1 (fr) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP0817775B1 (fr) * 1995-03-30 2001-09-12 Pfizer Inc. Derives de quinazoline
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
CZ298230B6 (cs) 1998-04-29 2007-08-01 Osi Pharmaceuticals, Inc. Anhydrát a monohydrát N-(3-ethinylfenyl)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin mesylátu

Also Published As

Publication number Publication date
PA8491901A1 (es) 2001-12-14
BRPI0001486B1 (pt) 2019-01-29
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
AP1655A (en) 2006-09-01
AU781402B2 (en) 2005-05-19
CO5160273A1 (es) 2002-05-30
DE60032275D1 (de) 2007-01-25
IS5411A (is) 2000-10-02
CZ20001155A3 (cs) 2001-03-14
SV2002000047A (es) 2002-01-23
UY26086A1 (es) 2000-10-31
HUP0001353A2 (hu) 2001-05-28
CA2302965A1 (fr) 2000-09-30
NO20001648D0 (no) 2000-03-30
CA2427221A1 (fr) 2000-09-30
CN100351242C (zh) 2007-11-28
HUP0001353A3 (en) 2002-01-28
UA80955C2 (en) 2007-11-26
EP1044969B1 (fr) 2006-12-13
EA200000274A2 (ru) 2000-10-30
NZ512818A (en) 2003-01-31
CA2427221C (fr) 2008-09-16
KR20020084903A (ko) 2002-11-13
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
ATE348098T1 (de) 2007-01-15
NO321952B1 (no) 2006-07-24
EP1044969A3 (fr) 2000-11-29
EA004654B1 (ru) 2004-06-24
JP4074509B2 (ja) 2008-04-09
IL135245A0 (en) 2001-05-20
CN1276370A (zh) 2000-12-13
MY136270A (en) 2008-09-30
HK1029790A1 (en) 2001-04-12
EA200201245A1 (ru) 2003-04-24
HRP20000182A2 (en) 2001-04-30
BG104278A (en) 2001-08-31
HU227698B1 (en) 2011-12-28
ID25427A (id) 2000-10-05
NO20001648L (no) 2000-10-02
DE60032275T2 (de) 2007-07-12
AP1265A (en) 2004-03-26
AU2005201494A1 (en) 2005-05-05
SG115536A1 (en) 2005-10-28
AU2005201494B2 (en) 2008-02-07
US6476040B1 (en) 2002-11-05
TW553939B (en) 2003-09-21
JP2000290262A (ja) 2000-10-17
UA70928C2 (uk) 2004-11-15
SG121687A1 (en) 2006-05-26
ZA200001586B (en) 2001-10-01
GEP20022653B (en) 2002-03-25
EA200201244A1 (ru) 2003-04-24
SK287339B6 (sk) 2010-07-07
NZ503683A (en) 2001-09-28
ES2278578T3 (es) 2007-08-16
CN1699350A (zh) 2005-11-23
CZ299426B6 (cs) 2008-07-23
EA200000274A3 (ru) 2003-02-27
CA2302965C (fr) 2004-02-17
OA11335A (en) 2003-12-10
TR200000837A2 (tr) 2000-11-21
CR6165A (es) 2008-10-10
PE20001599A1 (es) 2001-01-18
KR100430210B1 (ko) 2004-05-03
SK4442000A3 (en) 2000-10-09
DZ3030A1 (fr) 2004-03-27
EG22506A (en) 2003-03-31
EP1044969A2 (fr) 2000-10-18
JP3420549B2 (ja) 2003-06-23
EE04589B1 (et) 2006-02-15
KR20010014658A (ko) 2001-02-26
KR100430209B1 (ko) 2004-05-03
EE200000255A (et) 2000-12-15
PT1044969E (pt) 2007-05-31
JP2003176274A (ja) 2003-06-24
BRPI0001486B8 (pt) 2021-05-25
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
EA005561B1 (ru) 2005-04-28
BR0001486A (pt) 2001-05-02
IS2468B (is) 2008-12-15
CN1215061C (zh) 2005-08-17
DK1044969T3 (da) 2007-04-23
AR018705A1 (es) 2001-11-28
NO20054715L (no) 2000-10-02
BG65194B1 (bg) 2007-06-29
YU13200A (sh) 2002-10-18
PL339330A1 (en) 2000-10-09
GT200000037A (es) 2001-09-21
EA005892B1 (ru) 2005-06-30
RS49836B (sr) 2008-08-07
HU0001353D0 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
MA25087A1 (fr) Procedes et produits intermediaires pour la preparation de composes anti-cancereux
HUP0102711A3 (en) Epothilone derivatives and pharmaceutical compositions containing them and process for preparation the same
HUP0201376A2 (en) Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds
MA23528A1 (fr) Procede de preparation de produits pharmaceutiques
HUP0201068A2 (en) Pharmaceutical compositions of erythropoietin
FR2797769B1 (fr) Produits radiopharmaceutiques et leur procede de preparation
FR2682088B1 (fr) Conditionnement pour la preparation extemporanee de produits medicamenteux.
HUP0304042A2 (hu) Cefemszármazékok és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására
MA23518A1 (fr) Procede de preparation de produits pharmaceutiques
GB9802088D0 (en) Pharmaceutical products
FR2785785B1 (fr) Distributeur de produits pour lave-vaisselle
EP1176150A4 (fr) Procede de preparation de derives de trifluorothymidine
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
AU6233600A (en) Process for the production of epothiolone b and derivatives as well as intermediate products for this process
NO20022956D0 (no) Fremgangsmåte for fremstilling av nitroguanidin
HUP0100957A3 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same, their use and pharmaceutical compositions containing them
FR2802789B1 (fr) Plate-forme d'enlevement de produits permettant une preparation rapide des produits
GB2355912B (en) Production of crab food products
FR2792915B1 (fr) Distributeur de produits liquides
FR2789566B1 (fr) Systeme d'aide a l'embrochage de produits a rotir
FR2782985B1 (fr) Barquette pour le conditionnement de produits alimentaires generant des exsudats
IL140300A0 (en) Process for the preparation of amides
IL129154A0 (en) Pharmaceutical preparation useful for the prevention of cancer metastasis
FI20020288A (fi) Menetelmä etsyymikatalysoitujen tuotteiden valmistamiseksi ja samanaikaiseksi erottamiseksi
FR2747679B1 (fr) Utilisation de composes organometalliques pour la preparation de produits radiopharmaceutiques